CN103025340A - 芦荟(Aloe vera)的抗病毒特性和获得性免疫缺陷综合征(AIDS)的治疗 - Google Patents
芦荟(Aloe vera)的抗病毒特性和获得性免疫缺陷综合征(AIDS)的治疗 Download PDFInfo
- Publication number
- CN103025340A CN103025340A CN2011800360961A CN201180036096A CN103025340A CN 103025340 A CN103025340 A CN 103025340A CN 2011800360961 A CN2011800360961 A CN 2011800360961A CN 201180036096 A CN201180036096 A CN 201180036096A CN 103025340 A CN103025340 A CN 103025340A
- Authority
- CN
- China
- Prior art keywords
- aloe
- aids
- aloin
- methylol
- emodin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000011399 aloe vera Nutrition 0.000 title claims abstract description 138
- 208000030507 AIDS Diseases 0.000 title claims abstract description 121
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 32
- 235000002961 Aloe barbadensis Nutrition 0.000 title abstract description 14
- 244000186892 Aloe vera Species 0.000 title abstract description 14
- 230000000840 anti-viral effect Effects 0.000 title description 2
- 241001116389 Aloe Species 0.000 claims abstract description 129
- 239000000203 mixture Substances 0.000 claims abstract description 69
- 239000000284 extract Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 51
- 150000004056 anthraquinones Chemical class 0.000 claims abstract description 44
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 37
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 28
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 27
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 10
- 229930195729 fatty acid Natural products 0.000 claims abstract description 10
- 239000000194 fatty acid Substances 0.000 claims abstract description 10
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 229940088594 vitamin Drugs 0.000 claims abstract description 6
- 239000011782 vitamin Substances 0.000 claims abstract description 6
- 235000013343 vitamin Nutrition 0.000 claims abstract description 6
- 229930003231 vitamin Natural products 0.000 claims abstract description 6
- 239000002184 metal Substances 0.000 claims abstract description 5
- 229910052751 metal Inorganic materials 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 claims description 88
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 claims description 79
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 claims description 71
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 claims description 62
- 229920001282 polysaccharide Polymers 0.000 claims description 60
- 239000005017 polysaccharide Substances 0.000 claims description 60
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 54
- 238000002360 preparation method Methods 0.000 claims description 54
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 claims description 45
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 45
- 239000010282 Emodin Substances 0.000 claims description 36
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 36
- 208000024891 symptom Diseases 0.000 claims description 34
- 230000000576 supplementary effect Effects 0.000 claims description 31
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 27
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 27
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 27
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 27
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 27
- 241000555825 Clupeidae Species 0.000 claims description 26
- -1 glycosyl anthrone Chemical compound 0.000 claims description 22
- FCDLCPWAQCPTKC-UHFFFAOYSA-N Rhein Chemical compound C1=CC=C2C(=O)C3=CC(C(=O)O)=CC(O)=C3C(=O)C2=C1O FCDLCPWAQCPTKC-UHFFFAOYSA-N 0.000 claims description 19
- 229940006091 aloe polysaccharide Drugs 0.000 claims description 19
- UBCNQVZKORYVCA-UHFFFAOYSA-N 1,5-dihydroxyanthraquinone-3-carboxylic acid Natural products C1=CC(O)=C2C(=O)C3=CC(C(=O)O)=CC(O)=C3C(=O)C2=C1 UBCNQVZKORYVCA-UHFFFAOYSA-N 0.000 claims description 18
- MUVQKFGNPGZBII-UHFFFAOYSA-N 1-anthrol Chemical compound C1=CC=C2C=C3C(O)=CC=CC3=CC2=C1 MUVQKFGNPGZBII-UHFFFAOYSA-N 0.000 claims description 18
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 claims description 18
- 238000001990 intravenous administration Methods 0.000 claims description 17
- 102000000588 Interleukin-2 Human genes 0.000 claims description 16
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 14
- 229920002581 Glucomannan Polymers 0.000 claims description 13
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 229940046240 glucomannan Drugs 0.000 claims description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 12
- FOANPUVWJFUIQP-UHFFFAOYSA-N 1,2-diacetylanthracene-9,10-dione Chemical class C1=CC=C2C(=O)C3=C(C(C)=O)C(C(=O)C)=CC=C3C(=O)C2=C1 FOANPUVWJFUIQP-UHFFFAOYSA-N 0.000 claims description 12
- 230000035992 intercellular communication Effects 0.000 claims description 12
- 241001597008 Nomeidae Species 0.000 claims description 11
- 206010057248 Cell death Diseases 0.000 claims description 10
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 10
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 10
- 230000009089 cytolysis Effects 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- YYOOOMNEONKALI-UHFFFAOYSA-N 1,8-dihydroxy-2,4,5,7-tetranitroanthracene-9,10-dione Chemical compound O=C1C2=C([N+]([O-])=O)C=C([N+]([O-])=O)C(O)=C2C(=O)C2=C1C([N+]([O-])=O)=CC([N+]([O-])=O)=C2O YYOOOMNEONKALI-UHFFFAOYSA-N 0.000 claims description 9
- BMTMWCVGAVWDRA-UHFFFAOYSA-N 1-(hydroxymethyl)anthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2CO BMTMWCVGAVWDRA-UHFFFAOYSA-N 0.000 claims description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 9
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 9
- AFHJQYHRLPMKHU-OSYMLPPYSA-N aloin A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-OSYMLPPYSA-N 0.000 claims description 9
- 229930182482 anthraquinone glycoside Natural products 0.000 claims description 9
- 150000008139 anthraquinone glycosides Chemical class 0.000 claims description 9
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 claims description 9
- 229960001577 dantron Drugs 0.000 claims description 9
- 238000006297 dehydration reaction Methods 0.000 claims description 9
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 9
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 9
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000020778 linoleic acid Nutrition 0.000 claims description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229940098330 gamma linoleic acid Drugs 0.000 claims description 8
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 8
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 7
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 claims description 4
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 235000021290 n-3 DPA Nutrition 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 13
- 238000007911 parenteral administration Methods 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 abstract description 5
- 208000019902 chronic diarrheal disease Diseases 0.000 abstract description 4
- 230000001079 digestive effect Effects 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 230000004580 weight loss Effects 0.000 abstract description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical class CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 64
- 150000004804 polysaccharides Chemical class 0.000 description 35
- 230000000694 effects Effects 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 210000000822 natural killer cell Anatomy 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 210000001616 monocyte Anatomy 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- XOYXESIZZFUVRD-UVSAJTFZSA-N (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]ox Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C(O)=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-N 0.000 description 11
- 229960005327 acemannan Drugs 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 108010031099 Mannose Receptor Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000011514 reflex Effects 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 4
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108010041397 CD4 Antigens Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000023402 cell communication Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 240000007474 Aloe arborescens Species 0.000 description 2
- 244000101643 Aloe ferox Species 0.000 description 2
- 235000015858 Aloe ferox Nutrition 0.000 description 2
- 206010008531 Chills Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 206010038705 Respiratory moniliasis Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004395 cytoplasmic granule Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002478 diastatic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- HSYLKWSCFRLSKB-UHFFFAOYSA-N 1,5-diamino-4,8-dihydroxyanthracene-9,10-dione Chemical compound O=C1C2=C(N)C=CC(O)=C2C(=O)C2=C1C(O)=CC=C2N HSYLKWSCFRLSKB-UHFFFAOYSA-N 0.000 description 1
- 235000004509 Aloe arborescens Nutrition 0.000 description 1
- 235000003011 Aloe arborescens var natalensis Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010057854 Cerebral Toxoplasmosis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000007521 HIV Seropositivity Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 241000381142 Pachydermia Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010058878 Salmonella sepsis Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Virology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (46)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36735810P | 2010-07-23 | 2010-07-23 | |
US61/367,358 | 2010-07-23 | ||
PCT/US2011/044652 WO2012012513A1 (en) | 2010-07-23 | 2011-07-20 | Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103025340A true CN103025340A (zh) | 2013-04-03 |
CN103025340B CN103025340B (zh) | 2014-12-24 |
Family
ID=45494120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180036096.1A Active CN103025340B (zh) | 2010-07-23 | 2011-07-20 | 芦荟(Aloe vera)组合物及其在制备抗病毒和治疗获得性免疫缺陷综合征(AIDS)药物中的应用 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120022018A1 (zh) |
EP (1) | EP2595643A4 (zh) |
JP (1) | JP2013531071A (zh) |
KR (1) | KR20130062329A (zh) |
CN (1) | CN103025340B (zh) |
AP (1) | AP2013006738A0 (zh) |
AR (1) | AR082335A1 (zh) |
AU (1) | AU2011282200B2 (zh) |
BR (1) | BR112013001717A2 (zh) |
CA (1) | CA2804622A1 (zh) |
HK (1) | HK1182336A1 (zh) |
MX (1) | MX2013000670A (zh) |
NZ (3) | NZ720863A (zh) |
RU (1) | RU2013100188A (zh) |
SG (1) | SG186999A1 (zh) |
TW (1) | TW201206460A (zh) |
WO (1) | WO2012012513A1 (zh) |
ZA (1) | ZA201300583B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418410A (zh) * | 2015-12-21 | 2016-03-23 | 武汉大学 | 大黄素衍生物及其在制备抗hiv-1药物中的应用 |
CN106831397A (zh) * | 2016-12-12 | 2017-06-13 | 东北师范大学 | 一种蒽醌类化合物及其制备方法和医用用途 |
CN109803540A (zh) * | 2016-07-07 | 2019-05-24 | 美国康宝莱国际公司 | 使用纯化的(脱色的)芦荟叶干燥汁的处理方法 |
CN111320541A (zh) * | 2020-03-26 | 2020-06-23 | 四川大学华西医院 | 一种防治病毒疾病的化合物及其应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012174253A1 (en) * | 2011-06-14 | 2012-12-20 | Coats Aloe International, Inc. | Methods for aloe processing |
WO2017126995A1 (en) | 2016-01-18 | 2017-07-27 | Alessa Nadiah Abdulkarim A | Composition for treatment and preventative of the human papilloma virus hpv inffction, ulcerations and boils |
KR101988757B1 (ko) * | 2017-12-19 | 2019-06-12 | 가톨릭대학교 산학협력단 | 1,2-디하이드록시-3-메틸안트라퀴논을 유효성분으로 하는 간암 예방 또는 치료용 조성물 |
JP2021519367A (ja) | 2018-03-28 | 2021-08-10 | ハーバライフ・インターナショナル・オブ・アメリカ・インコーポレイテッド | 多糖のアセチル化 |
KR20230011537A (ko) | 2021-07-13 | 2023-01-25 | 주식회사 케이제이엠바이오 | 알로에 노루궁뎅이버섯 균사체 발효물 함유 분말의 제조방법 및 이에 따라 제조된 분말을 포함하는 기능성 식품 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118673A (en) * | 1982-05-07 | 1992-06-02 | Carrington Laboratories, Inc. | Uses of aloe products |
US6083508A (en) * | 1998-05-19 | 2000-07-04 | Avalos; Ramiro Estrada | Method of processing aloe leaves |
CN1589677A (zh) * | 2004-03-16 | 2005-03-09 | 大连理工大学 | 无色透明脱苦稳定芦荟凝胶汁的清洁生产方法 |
CN1778310A (zh) * | 2004-11-18 | 2006-05-31 | 深圳市武大金球中药现代化工程技术研究中心 | 大黄素、大黄多糖在抗人类免疫缺陷病素(hiv)中的应用 |
CN101070354A (zh) * | 2007-05-18 | 2007-11-14 | 中南大学 | 一种利用芦荟同时生产芦荟多糖粉、芦荟活性水的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4917890A (en) * | 1985-06-28 | 1990-04-17 | Carrington Laboratories, Inc. | Processes for preparation of aloe products, products produced thereby and compositions thereof |
US4851224A (en) * | 1986-06-05 | 1989-07-25 | Carrington Laboratories, Inc. | Process for preparation of aloe products |
US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
US5824659A (en) * | 1996-09-04 | 1998-10-20 | Board Of Regents, The University Of Texas System | Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation |
US20040063624A1 (en) * | 1999-04-08 | 2004-04-01 | Andreas Kage | Method of inhibiting the transition of free HIV virus through the cllular mucosal barrier |
AU2003300167B2 (en) * | 2003-12-31 | 2010-09-16 | K-Pax Vitamins, Inc. | Nutrient compositions and methods for enhanced effectiveness of the immune system |
US8604187B2 (en) * | 2010-01-14 | 2013-12-10 | North Texas Medical Associates | Compositions and methods of aloe polysaccharides |
-
2011
- 2011-07-20 US US13/187,222 patent/US20120022018A1/en not_active Abandoned
- 2011-07-20 MX MX2013000670A patent/MX2013000670A/es active IP Right Grant
- 2011-07-20 AP AP2013006738A patent/AP2013006738A0/xx unknown
- 2011-07-20 CA CA2804622A patent/CA2804622A1/en not_active Abandoned
- 2011-07-20 NZ NZ720863A patent/NZ720863A/en unknown
- 2011-07-20 NZ NZ701262A patent/NZ701262A/en unknown
- 2011-07-20 NZ NZ605466A patent/NZ605466A/en unknown
- 2011-07-20 AU AU2011282200A patent/AU2011282200B2/en active Active
- 2011-07-20 WO PCT/US2011/044652 patent/WO2012012513A1/en active Application Filing
- 2011-07-20 SG SG2013001748A patent/SG186999A1/en unknown
- 2011-07-20 CN CN201180036096.1A patent/CN103025340B/zh active Active
- 2011-07-20 EP EP11810330.8A patent/EP2595643A4/en not_active Withdrawn
- 2011-07-20 JP JP2013520831A patent/JP2013531071A/ja active Pending
- 2011-07-20 KR KR1020137004429A patent/KR20130062329A/ko not_active Application Discontinuation
- 2011-07-20 BR BR112013001717A patent/BR112013001717A2/pt not_active IP Right Cessation
- 2011-07-20 RU RU2013100188/15A patent/RU2013100188A/ru not_active Application Discontinuation
- 2011-07-22 TW TW100126070A patent/TW201206460A/zh unknown
- 2011-07-22 AR ARP110102674A patent/AR082335A1/es unknown
-
2013
- 2013-01-22 ZA ZA2013/00583A patent/ZA201300583B/en unknown
- 2013-08-22 HK HK13109862.1A patent/HK1182336A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118673A (en) * | 1982-05-07 | 1992-06-02 | Carrington Laboratories, Inc. | Uses of aloe products |
US6083508A (en) * | 1998-05-19 | 2000-07-04 | Avalos; Ramiro Estrada | Method of processing aloe leaves |
CN1589677A (zh) * | 2004-03-16 | 2005-03-09 | 大连理工大学 | 无色透明脱苦稳定芦荟凝胶汁的清洁生产方法 |
CN1778310A (zh) * | 2004-11-18 | 2006-05-31 | 深圳市武大金球中药现代化工程技术研究中心 | 大黄素、大黄多糖在抗人类免疫缺陷病素(hiv)中的应用 |
CN101070354A (zh) * | 2007-05-18 | 2007-11-14 | 中南大学 | 一种利用芦荟同时生产芦荟多糖粉、芦荟活性水的方法 |
Non-Patent Citations (2)
Title |
---|
ELSOHLY MA ET AL: "<Determination of the anthraquinones aloe-emodin and aloin-A by liquid chromatogrphy with mass spectrometric and diode array detection>", <JOURNAL OF AOAC INTERNATIONAL> * |
WERTZ PW: "<Essential fatty acids and dietary stress>", <TOXICOLOGH AND INDUSTRIAL HEALTH> * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418410A (zh) * | 2015-12-21 | 2016-03-23 | 武汉大学 | 大黄素衍生物及其在制备抗hiv-1药物中的应用 |
CN109803540A (zh) * | 2016-07-07 | 2019-05-24 | 美国康宝莱国际公司 | 使用纯化的(脱色的)芦荟叶干燥汁的处理方法 |
CN106831397A (zh) * | 2016-12-12 | 2017-06-13 | 东北师范大学 | 一种蒽醌类化合物及其制备方法和医用用途 |
CN106831397B (zh) * | 2016-12-12 | 2019-07-26 | 东北师范大学 | 一种蒽醌类化合物及其制备方法和医用用途 |
CN111320541A (zh) * | 2020-03-26 | 2020-06-23 | 四川大学华西医院 | 一种防治病毒疾病的化合物及其应用 |
CN111320541B (zh) * | 2020-03-26 | 2023-05-26 | 四川大学华西医院 | 一种防治病毒疾病的化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2595643A1 (en) | 2013-05-29 |
US20120022018A1 (en) | 2012-01-26 |
BR112013001717A2 (pt) | 2016-05-31 |
AP2013006738A0 (en) | 2013-02-28 |
EP2595643A4 (en) | 2013-12-25 |
HK1182336A1 (zh) | 2013-11-29 |
SG186999A1 (en) | 2013-02-28 |
AU2011282200A1 (en) | 2013-01-24 |
RU2013100188A (ru) | 2014-08-27 |
CN103025340B (zh) | 2014-12-24 |
AU2011282200B2 (en) | 2015-03-19 |
TW201206460A (en) | 2012-02-16 |
WO2012012513A1 (en) | 2012-01-26 |
NZ720863A (en) | 2016-10-28 |
AR082335A1 (es) | 2012-11-28 |
MX2013000670A (es) | 2013-02-27 |
CA2804622A1 (en) | 2012-01-26 |
ZA201300583B (en) | 2014-06-25 |
NZ701262A (en) | 2016-06-24 |
NZ605466A (en) | 2015-04-24 |
KR20130062329A (ko) | 2013-06-12 |
JP2013531071A (ja) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103025340B (zh) | 芦荟(Aloe vera)组合物及其在制备抗病毒和治疗获得性免疫缺陷综合征(AIDS)药物中的应用 | |
ES2886951T3 (es) | Composición para su uso en la modulación de la microbiota | |
RU2469719C2 (ru) | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА | |
US20070224216A1 (en) | Methods and Compositions Related to Antiviral Therapy Using Algae and Cyanobacteria | |
JP5596704B2 (ja) | フコキサンチン抽出物を含有する組成物 | |
CN108013454A (zh) | 妇科炎症专用型临床营养配方及其制备方法 | |
WO2005076761A2 (en) | Composition for preenting a cold | |
CN104489681A (zh) | 一种具有增强免疫力功能的组合物、保健品及其制备方法 | |
CN104799286B (zh) | 一种用于提高免疫力的组合物及其制备方法 | |
WO2021103776A1 (zh) | 一种具有辅助防治儿童、青少年心理抑郁的作用的复合制剂 | |
Zhang et al. | Immunomodulatory activity of a fructooligosaccharide isolated from burdock roots | |
CN110772578A (zh) | 一种用于癌症防治的人体免疫力增强剂及其制备方法 | |
CN108813610A (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
CN101336709A (zh) | 一种抗疲劳营养制剂 | |
JP2003146887A (ja) | Nk細胞活性化作用を有する製剤および飲食品 | |
CN113769029A (zh) | 一种改善肠道吸收、免疫功能的药食同源本草组合物 | |
Ma et al. | Influence of Ligustrum lucidum and Schisandra chinensis fruits on antioxidative metabolism and immunological parameters of layer chicks | |
CN105535927A (zh) | 一种用于治疗流感、上呼吸道感染、病毒性肺炎的药物 | |
CN108851071A (zh) | 沙棘vp营养组合物及其制备方法和应用 | |
JP2007204488A (ja) | 免疫賦活効果を相乗的に増強した製剤 | |
JP6476043B2 (ja) | 消化性潰瘍の予防又は治療剤,及び予防又は治療のための食品添加物 | |
OA17066A (en) | Anti-viral properties of aloe vera and Aquired Immune Deficiency Syndrome (AIDS) treatment. | |
AU2021105111A4 (en) | Drug for treating cancer pain, preparation method and use thereof | |
CN107970437A (zh) | 虫草克癌基因肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1182336 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BISI PUKE BIOLOGICAL SCIENCES CO., LTD. Free format text: FORMER OWNER: NORTH TEXAS MEDICAL ASSOCIATES Effective date: 20150106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150106 Address after: American Texas Patentee after: Biss F C bioscience Ltd Address before: American Texas Patentee before: North Texas Medical Associates |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1182336 Country of ref document: HK |